Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | CTSK | P43235 | 8/20 | 0.53 |
| ▸ | CTSS | P25774 | 2/20 | 0.50 |
| ▸ | CTSL | P07711 | 2/20 | 0.50 |
| ▸ | CTSB | P07858 | 2/20 | 0.50 |
| ▸ | PGR | P06401 | 1/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | TYR | P14679 | 1/20 | 0.48 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.47 |
| ▸ | CAPN2 | P17655 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7250149 | 1.00 | NPC1 (0.56) | NPC1RAB9ASMN1; SMN2LMNACTSK | |
| Lithium SCHEMBL7159425 | 0.99 | NPC1 (0.55) | NPC1RAB9ASMN1; SMN2LMNACTSK | |
| SCHEMBL7159417 | 0.99 | NPC1 (0.55) | NPC1RAB9ASMN1; SMN2LMNACTSK | |
| SCHEMBL7160572 | 0.90 | NPC1 (0.53) | NPC1RAB9ASMN1; SMN2LMNACTSK | |
| SCHEMBL27492977 | 0.90 | NPC1 (0.53) | NPC1RAB9ASMN1; SMN2LMNACTSK | |
| SCHEMBL27557439 | 0.89 | CTSL (0.55) | NPC1RAB9ASMN1; SMN2LMNACTSK | |
| SCHEMBL3844143 | 0.89 | MEN1 (0.48) | NPC1RAB9ASMN1; SMN2CTSKCTSS | |
| SCHEMBL21458077 | 0.89 | MEN1 (0.48) | NPC1RAB9ASMN1; SMN2CTSKCTSS | |
| Lithium Ion SCHEMBL7159421 | 0.88 | SMN1; SMN2 (0.51) | NPC1RAB9ASMN1; SMN2LMNACTSK | |
| SCHEMBL6183994 | 0.85 | CTSS (0.72) | CTSKCTSSCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1171870-C | Cysteine protease inhibitors | ʷ��˿�������ȳ�ķ����˾ | 2004-10-20 | — | — | CN | disclosed |
| US-20040180927-A1 | Inhibitors of cysteine protease | SMITHKLINE BEECHAM CORPORATION | 2004-09-16 | — | — | US | disclosed |
| EP-0936912-B1 | INHIBITORS OF CYSTEINE PROTEASE | SMITHKLINE BEECHAM CORP (US) | 2004-02-11 | — | — | EP | disclosed |
| US-6586466-B2 | Enzyme inhibitor for use in the treatment of bone, oral, arthritic, paget's and hypercalcemic diseases | SMITHKLINE BEECHAM CORPORATION | 2003-07-01 | — | — | US | disclosed |
| US-6562842-B2 | Osteoporosis, oral diseases | SMITHKLINE BEECHAM CORPORATION | 2003-05-13 | — | — | US | disclosed |
| EP-1093367-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2003-03-05 | — | — | EP | disclosed |
| EP-1019046-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM (US) | 2002-11-27 | — | — | EP | disclosed |
| US-20020173469-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-11-21 | — | — | US | disclosed |
| US-20020156018-A1 | Treatment of parasitic diseases by inhibition of cysteine proteases of the papain superfamily | THOMPSON SCOTT KEVIN (US) | 2002-10-24 | — | — | US | disclosed |
| US-20020128476-A1 | Inhibitors of cysteine protease | SMITHKLINE BEECHAM CORPORATION | 2002-09-12 | — | — | US | disclosed |
| CN-1232399-A | Cysteine protease inhibitors | SMITHKLINE BEECHAM CORP (US) | 1999-10-20 | — | — | CN | disclosed |
| EP-0936912-A4 | INHIBITORS OF CYSTEINE PROTEASE | SMITHKLINE BEECHAM CORP (US) | 1999-10-13 | — | — | EP | disclosed |
| EP-0936912-A1 | INHIBITORS OF CYSTEINE PROTEASE | SMITHKLINE BEECHAM CORPORATION (US) | 1999-08-25 | — | — | EP | disclosed |
| EP-0934291-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-08-11 | — | — | EP | disclosed |
| EP-0934291-A4 | — | SMITHKLINE BEECHAM CORP (US) | 1999-08-11 | — | — | EP | disclosed |
| WO-1998048799-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-11-05 | — | — | WO | disclosed |
| WO-1998005336-A1 | INHIBITORS OF CYSTEINE PROTEASE | SMITHKLINE BEECHAM CORPORATION (US) | 1998-02-12 | — | — | WO | disclosed |
| WO-1997016433-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-05-09 | — | — | WO | disclosed |
| US-5578608-A | HIV PROTEASE INHIBITOR | ELI LILLY AND COMPANY (US) | 1996-11-26 | — | — | US | disclosed |
| EP-0575097-A1 | 2,3-Bis-carboxamidomethyl substituted oxiranes as inhibitors of HIV protease and their use for the treatment of AIDS | ELI LILLY AND COMPANY (US) | 1993-12-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180927-A1 | Inhibitors of cysteine protease | CTSK, CTSZ, CTSS | NPC1 275/4885RAB9A 743/4885SMN1; SMN2 3802/4885 |
| US-20020128476-A1 | Inhibitors of cysteine protease | CTRC, RCE1, CTRL | NPC1 499/4885RAB9A 2169/4885SMN1; SMN2 4556/4885 |
| US-20020156018-A1 | Treatment of parasitic diseases by inhibition of cysteine proteases of the papain superfamily | PEPD, PREP, CPN1 | NPC1 844/4885RAB9A 2225/4885SMN1; SMN2 4763/4885 |
| US-20020173469-A1 | Protease inhibitors | CTSK, CTSZ, CTSG | NPC1 862/4885RAB9A 1337/4885SMN1; SMN2 4791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.